<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000777</url>
  </required_header>
  <id_info>
    <org_study_id>IC/LV/MEL-ZN/SFC</org_study_id>
    <nct_id>NCT03000777</nct_id>
  </id_info>
  <brief_title>Oral Melatonin Plus Zinc Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)</brief_title>
  <acronym>MELATOZINC</acronym>
  <official_title>An Unicentric, Double-blind, Placebo Controlled, Phase IV Clinical Trial of Oral Melatonin Plus Zinc to Evaluate Relieving Self-reported Fatigue in CFS/ME</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Viñas, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorio Echevarne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Viñas, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of oral melatonin plus zinc
      supplementation in relieving self-reported fatigue in CFS/ME
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a complex medical condition,
      characterized by severe disabling fatigue with no known cause, no established diagnostic
      tests, and no universally effective treatment. No studies have evaluated symptomatic
      treatment using oral melatonin plus zinc supplementation in CFS/ME. The primary endpoint was
      to assess the effect of melatonin plus zinc supplementation on self-reported fatigue.
      Secondary measures included self-reported outcomes of sleep problems, anxiety/depression,
      dysautonomia, QoL and side-effects during treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate relieving self-reported fatigue using the Fatigue Impact Scale 40-items (FIS 40) questionnaire after oral melatonin plus zinc administration</measure>
    <time_frame>within the first 16 weeks (plus 4 weeks with no treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects during treatment.</measure>
    <time_frame>within the first 16 weeks (plus 4 weeks with no treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported sleep quality through the Pittsburgh Sleep Quality Index (PSQI) questionnaire.</measure>
    <time_frame>within the first 16 weeks (plus 4 weeks with no treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported anxiety/depression through the Hospital Anxiety and Depression Scale (HADS) questionnaire.</measure>
    <time_frame>within the first 16 weeks (plus 4 weeks with no treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported dysautonomia using the Composite Autonomic Symptom Score 31-items (COMPASS 31) questionnaire.</measure>
    <time_frame>within the first 16 weeks (plus 4 weeks with no treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported QoL through the Short Form Health Survey 36-items (SF-36) questionnaire.</measure>
    <time_frame>within the first 16 weeks (plus 4 weeks with no treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Fatigue Syndrome, Chronic</condition>
  <condition>Myalgic Encephalomyelitis</condition>
  <arm_group>
    <arm_group_label>Melatonin plus Zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin plus Zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Isomaltose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin plus zinc</intervention_name>
    <description>Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks</description>
    <arm_group_label>Melatonin plus Zinc</arm_group_label>
    <other_name>MelatoZinc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Isomaltose o.d. 1 hour before going to bed during 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CFS patient based on the 1994 Centers for Disease Control and Prevention/Fukuda
             definition.

          -  Patient who provided signed informed consent.

        Exclusion Criteria:

          -  Patients who are participating in another clinical trial of the same or different
             nature previous 30 days prior to inclusion.

          -  Any subject that, in the judgment of the investigator, is not able to follow the
             instructions or to perform a good completion of the treatment.

          -  Subjects that do not provide signed informed consent.

          -  Patients who are receiving any of the drugs or products that may interfere with the
             results, and whose withdrawal could be a relevant medical problem.

          -  Patients receiving oral anticoagulants.

          -  Pregnancy or lactation

          -  Patients with hypersensitivity to melatonin and/or zinc.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Alegre, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebron University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Castro-Marrero J, Cordero MD, Sáez-Francas N, Jimenez-Gutierrez C, Aguilar-Montilla FJ, Aliste L, Alegre-Martin J. Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia? Antioxid Redox Signal. 2013 Nov 20;19(15):1855-60. doi: 10.1089/ars.2013.5346. Epub 2013 May 29.</citation>
    <PMID>23600892</PMID>
  </reference>
  <reference>
    <citation>Castro-Marrero J, Cordero MD, Segundo MJ, Sáez-Francàs N, Calvo N, Román-Malo L, Aliste L, Fernández de Sevilla T, Alegre J. Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? Antioxid Redox Signal. 2015 Mar 10;22(8):679-85. doi: 10.1089/ars.2014.6181. Epub 2014 Dec 18.</citation>
    <PMID>25386668</PMID>
  </reference>
  <reference>
    <citation>Castro-Marrero J, Sáez-Francàs N, Segundo MJ, Calvo N, Faro M, Aliste L, Fernández de Sevilla T, Alegre J. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome - A randomized, controlled, double-blind trial. Clin Nutr. 2016 Aug;35(4):826-34. doi: 10.1016/j.clnu.2015.07.010. Epub 2015 Jul 17.</citation>
    <PMID>26212172</PMID>
  </reference>
  <reference>
    <citation>Sáez-Francàs N, Calvo N, Alegre J, Castro-Marrero J, Ramírez N, Hernández-Vara J, Casas M. Childhood trauma in Chronic Fatigue Syndrome: focus on personality disorders and psychopathology. Compr Psychiatry. 2015 Oct;62:13-9. doi: 10.1016/j.comppsych.2015.06.010. Epub 2015 Jun 17.</citation>
    <PMID>26343462</PMID>
  </reference>
  <reference>
    <citation>Faro M, Sàez-Francás N, Castro-Marrero J, Aliste L, Fernández de Sevilla T, Alegre J. Gender differences in chronic fatigue syndrome. Reumatol Clin. 2016 Mar-Apr;12(2):72-7. doi: 10.1016/j.reuma.2015.05.007. Epub 2015 Jul 17. English, Spanish.</citation>
    <PMID>26190206</PMID>
  </reference>
  <reference>
    <citation>Calvo N, Sáez-Francàs N, Valero S, Alegre J, Casas M. Comorbid personality disorders in chronic fatigue syndrome patients: a marker of psychopathological severity. Actas Esp Psiquiatr. 2015 Mar-Apr;43(2):58-65. Epub 2015 Mar 1.</citation>
    <PMID>25812543</PMID>
  </reference>
  <reference>
    <citation>Faro M, Alegre J. [Fibromyalgia as a comorbid phenomenon in autoinflammatory diseases]. Med Clin (Barc). 2015 Jun 8;144(11):525. doi: 10.1016/j.medcli.2014.07.033. Epub 2014 Nov 26. Spanish.</citation>
    <PMID>25433788</PMID>
  </reference>
  <reference>
    <citation>Santamarina-Perez P, Eiroa-Orosa FJ, Rodriguez-Urrutia A, Qureshi A, Alegre J. Neuropsychological impairment in female patients with chronic fatigue syndrome: a preliminary study. Appl Neuropsychol Adult. 2014;21(2):120-7. doi: 10.1080/09084282.2013.771264. Epub 2013 Aug 13.</citation>
    <PMID>24826505</PMID>
  </reference>
  <reference>
    <citation>Sáez-Francàs N, Valero S, Calvo N, Gomà-I-Freixanet M, Alegre J, de Sevilla TF, Casas M. Chronic fatigue syndrome and personality: a case-control study using the Alternative Five Factor Model. Psychiatry Res. 2014 May 30;216(3):373-8. doi: 10.1016/j.psychres.2014.02.031. Epub 2014 Mar 3.</citation>
    <PMID>24630915</PMID>
  </reference>
  <reference>
    <citation>Docampo E, Escaramís G, Gratacòs M, Villatoro S, Puig A, Kogevinas M, Collado A, Carbonell J, Rivera J, Vidal J, Alegre J, Estivill X, Rabionet R. Genome-wide analysis of single nucleotide polymorphisms and copy number variants in fibromyalgia suggest a role for the central nervous system. Pain. 2014 Jun;155(6):1102-9. doi: 10.1016/j.pain.2014.02.016. Epub 2014 Feb 26.</citation>
    <PMID>24582949</PMID>
  </reference>
  <reference>
    <citation>Faro M, Sáez-Francàs N, Castro-Marrero J, Aliste L, Collado A, Alegre J. [Impact of the fibromyalgia in the chronic fatigue syndrome]. Med Clin (Barc). 2014 Jun 16;142(12):519-25. doi: 10.1016/j.medcli.2013.06.030. Epub 2014 Jan 2. Spanish.</citation>
    <PMID>24387955</PMID>
  </reference>
  <reference>
    <citation>Blazquez A, Ruiz E, Aliste L, García-Quintana A, Alegre J. The effect of fatigue and fibromyalgia on sexual dysfunction in women with chronic fatigue syndrome. J Sex Marital Ther. 2015;41(1):1-10. doi: 10.1080/0092623X.2013.864370. Epub 2014 Mar 11.</citation>
    <PMID>24274008</PMID>
  </reference>
  <reference>
    <citation>Valero S, Sáez-Francàs N, Calvo N, Alegre J, Casas M. The role of neuroticism, perfectionism and depression in chronic fatigue syndrome. A structural equation modeling approach. Compr Psychiatry. 2013 Oct;54(7):1061-7. doi: 10.1016/j.comppsych.2013.04.015. Epub 2013 Jun 5.</citation>
    <PMID>23759150</PMID>
  </reference>
  <reference>
    <citation>Curriu M, Carrillo J, Massanella M, Rigau J, Alegre J, Puig J, Garcia-Quintana AM, Castro-Marrero J, Negredo E, Clotet B, Cabrera C, Blanco J. Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. J Transl Med. 2013 Mar 20;11:68. doi: 10.1186/1479-5876-11-68.</citation>
    <PMID>23514202</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melatonin</keyword>
  <keyword>zinc</keyword>
  <keyword>Myalgic Encephalomyelitis</keyword>
  <keyword>Chronic Fatigue Syndrome</keyword>
  <keyword>sleep</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

